Ordinary shares, nominal value €0.10 per share
- Symbol
- No trading symbol declared
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 8.01, 9.01 · 8-K
DBV Technologies S.A.
DBVTFOTCEQUITYCurrent
Other Events
Item 8.01. Other Events On January 16, 2026, DBV Technologies S.A. (the “Company”) issued a press release entitled “DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March Financing.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Company context
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.
Current securities
Registered securities in this filing
DBV Technologies S.A. · 8-K · Filed 2026-01-20
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share
- Symbol
- DBVT
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events
On January 16, 2026, DBV Technologies S.A. (the “Company”) issued a press release entitled “DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March Financing.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Filed exhibits (1)
Exhibit 99.1 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if approved. DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced a supplementary financing of €166.7 Million (the “Exercise”) resulting from the full exercise of (i) 34,090,004 warrants attached to new ordinary shares issued by the Company on April 7, 2025 at an exercise price of €1.5939 (the “ABSA Warrants”) resulting in the issuance of 59,657,507 new ordinary shares of the Company (the “New Shares”) and (ii) 71,005,656 warrants issued by the Company on April 7, 2025 at an exercise price of €1.5764 (the “BS Warrants”) resulting in the issuance of 71,005,656 pre-funded warrants (the “Second Pre-Funded Warrants”), allowing its holders to subscribe for an aggregate of up to 124,259,898 new shares. Reminder of the…
Open exhibit ↗